Molecular markers of artemisinin resistance during falciparum malaria elimination in Eastern Myanmar

Artemisinin resistance in Plasmodium falciparum threatens global malaria elimination efforts. To contain and then eliminate artemisinin resistance in Eastern Myanmar a network of community-based malaria posts was instituted and targeted mass drug administration (MDA) with dihydroartemisinin-piperaqu...

Full description

Saved in:
Bibliographic Details
Published in:Malaria journal 2024-05, Vol.23 (1), p.138-11, Article 138
Main Authors: Thu, Aung Myint, Phyo, Aung Pyae, Pateekhum, Chanapat, Rae, Jade D, Landier, Jordi, Parker, Daniel M, Delmas, Gilles, Watthanaworawit, Wanitda, McLean, Alistair R D, Arya, Ann, Reyes, Ann, Li, Xue, Miotto, Olivo, Soe, Kyaw, Ashley, Elizabeth A, Dondorp, Arjen, White, Nicholas J, Day, Nicholas P, Anderson, Tim J C, Imwong, Mallika, Nosten, Francois, Smithuis, Frank
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antimalarials - pharmacology
Antimalarials - therapeutic use
Artemisinin resistance
Artemisinins - pharmacology
Artemisinins - therapeutic use
Child
Child, Preschool
Control
Cross-Sectional Studies
Disease Eradication - statistics & numerical data
Drug Resistance - genetics
Female
Humans
Identification and classification
Kelch13
Malaria
Malaria elimination
Malaria, Falciparum - epidemiology
Malaria, Falciparum - parasitology
Male
Mass Drug Administration
Middle Aged
Mutation
Myanmar
P. falciparum
Piperazines
Plasmodium falciparum
Plasmodium falciparum - drug effects
Plasmodium falciparum - genetics
Prevention
Quinolines - pharmacology
Quinolines - therapeutic use
Risk factors
Surveys
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Artemisinin resistance in Plasmodium falciparum threatens global malaria elimination efforts. To contain and then eliminate artemisinin resistance in Eastern Myanmar a network of community-based malaria posts was instituted and targeted mass drug administration (MDA) with dihydroartemisinin-piperaquine (three rounds at monthly intervals) was conducted. The prevalence of artemisinin resistance during the elimination campaign (2013-2019) was characterized. Throughout the six-year campaign Plasmodium falciparum positive blood samples from symptomatic patients and from cross-sectional surveys were genotyped for mutations in kelch-13-a molecular marker of artemisinin resistance. The program resulted in near elimination of falciparum malaria. Of 5162 P. falciparum positive blood samples genotyped, 3281 (63.6%) had K13 mutations. The prevalence of K13 mutations was 73.9% in 2013 and 64.4% in 2019. Overall, there was a small but significant decline in the proportion of K13 mutants (p 
ISSN:1475-2875
1475-2875
DOI:10.1186/s12936-024-04955-6